GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

In oncology, we were delighted that Jemperli received an expanded approval by the FDA for all adult patients with primary advanced or recurrent endometrial cancer. And Blenrep is now filed with ...

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at Replays of the webcasts will be available for at least 30 days following the events. Anaptys is ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

U.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...

The WuXi companies make the raw materials for cancer drugs Imbruvica and Jemperli, among other drugs, according to supply-chain analytics firm Qyobo. Among listed U.S. biotechs and pharmaceutical ...

As for its oncology portfolio, GSK owns Jemperli and Zejula. These are indicated for endometrial and ovarian cancer, respectively. This segment also grew, mainly due to their expanded approvals ...

Jemperli added £130 million to GSK’s top line compared with £108 million in second-quarter 2024, driven by new patient starts ...